The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous ...

PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

We have found that inhibition of the BCR–ABL tyrosine kinase, either by mutation ... Immunoblottings were performed using 1 μg/ml 4G10 monoclonal antibody against phosphotyrosine (Upstate ...